The Venture Codex

Participated · Series A · Dec 2025

Founded in 2018, Glovv offers a solution that creates emotion-driven, information-based, and visit-style reels tailored for beauty brands. The company issues free advertising codes so clients can amplify marketing reach without extra spend and supplies both original and clean versions of each reel for versatile use. Glovv has signed contracts with more than 1,500 brands and claims to be the fastest-growing player and market leader in beauty-reel production in Korea. It underscores its core strength as focusing only on what customers want, which has translated into rapid market adoption. Seeking further growth, Glovv plans to expand into the U.S. market in early next year and collaborate with local beauty brands. The firm recently marked its first-anniversary seminar, drawing 1,000 beauty-brand professionals and 100 venture investors, highlighting its industry traction. Financially, Glovv bolstered its balance sheet with a ₩3 billion Series A round in August backed by multiple institutional investors.

Led · Series A · Jun 2022

Qureator develops Microphysiological Systems (MPS) and Curiochips microfluidic technology to create high-throughput, 3D co-culture disease models that better recapitulate tissue microenvironments. Its platforms enable patient-derived models, target validation in 3D co-cultures, high-throughput screening, biomarker identification, and more predictive clinical response assessment. The company already targets applications across oncology, vascular biology, the blood–brain barrier, and other tissue-specific pathological models. Qureator plans to use the new funding to accelerate research activities and expand into additional disease areas. The company, formerly known as Curiochips, emphasizes improving clinical translatability compared with traditional animal models. Qureator is led by CEO Kyu Baek, who has a background in electrical and biomedical engineering research.

Led · Series A · Apr 2021

ImpriMed develops AI-powered live-cell drug sensitivity and predictive models to identify effective anticancer medicines for individual canine and feline blood cancers. Its core service measures live tumor-cell responses in a California lab and combines those measurements with biological data to produce a treatment report delivered to veterinarians within seven days. Veterinary services are fully commercialized (five canine and three feline services), generate revenue, and have been used by more than 350 U.S. veterinarians; the company says it has helped over 5,000 dogs with lymphoma and collected outcome follow-up on over half of those cases. ImpriMed has run validation work with data from 2,000 human blood-cancer patients and the Mayo Clinic Platform’s 3 million‑patient database. The company plans to expand its veterinary-to-human precision oncology efforts, with an AI multiple myeloma product targeting commercialization in 2025 and plans to commercialize services for human AML and non-Hodgkin’s lymphoma before the end of 2024. It also offers a live-cell CRO service to help drug developers measure compound efficacy on patient cells. The startup plans to use new funding to expand its drug-response prediction technology into human oncology, grow its team (about 40 staff) and broaden business-development pipelines. ImpriMed is a Palo Alto-based veterinary precision medicine company that uses artificial intelligence to predict which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia. It generates live data from chemosensitivity and immunophenotyping assays on patients’ fresh cancer cells to produce quantified drug response predictions for veterinary oncologists. Led by CEO and co‑founder Dr. Sungwon Lim, the company enables clinicians to make chemotherapy decisions with greater confidence prior to drug administration. To date ImpriMed has provided more than 2,000 services to community-treated canine patients. The company plans to use the new funding to develop additional prediction models for its current canine blood-cancer targets, scale up its customer network and expand pipelines to other types of cancers in dogs and cats. Financially, ImpriMed closed an $8m Pre-Series A round comprising $7.7m from venture capital investors and the remainder as a government grant. ImpriMed uses precision medicine techniques to test hundreds of drug responses on fresh biopsy samples from canine cancer patients, observing how live cancer cells react before treatment. The platform screens for the most effective chemotherapy options and excludes non-effective ones, then provides those results to veterinary oncologists. The company is currently focused on treating lymphoma in dogs. ImpriMed plans to roll out a clinical trial that will be performed primarily at SAGE Veterinary Centers in the Bay Area. For a limited time it is offering its service free of charge while completing the clinical trial and aims to help more than 500 dogs by 2020. The company was founded in 2017 and maintains an additional presence in Seoul, South Korea.

Led · Equity · Apr 2018

Enuma develops game-based, self-directed educational applications for children, with flagship product Todo Math designed to teach foundational math and literacy without adult assistance. Todo Math has recorded over 8 million downloads worldwide since its 2014 launch. The company recently expanded its product lineup with Todo English, launched last month in Korea, which combines game-based activities, worksheets, videos and parent progress reports via chatbots. Enuma also operates Kitkit School and Enuma Geulbang to address educational inequities and teach literacy to out-of-school children and multicultural families. Founded in 2012 and led by CEO Sooinn Lee, the company maintains offices in Berkeley, Seoul and Beijing. Financially, Enuma closed a $9M Series B in May 2020. Enuma develops game-based education software to help children—especially those who struggle due to physical, cognitive, cultural or economic constraints—learn reading, writing and math independently. The company is best known for Todo Math, a multi-award-winning math app launched in 2014 that has charted more than five million downloads worldwide. To reach children in developing countries, Enuma developed Kitkit School, which was selected as one of five finalists in the $15M Global Learning XPRIZE competition. The company says it will use investment to develop partnerships around the world and create a viable model to reach children underserved by traditional education systems. Enuma’s leadership includes Founder and CEO Sooinn Lee, an Ashoka Fellow. The company is headquartered in Berkeley and maintains offices in Seoul and Beijing. LocoMotive Labs builds Todo Math, a mobile math‑learning app for children ages three to eight that uses game‑design elements and Universal Design for Learning to accommodate different learning styles. The app offers exploration gameplay with treasure boxes and rewards, multiple input modes (writing or drag‑and‑drop), and customizable problem presentations to tailor lessons to users. Todo Math has been downloaded 1.1 million times overall, including about 350,000 downloads in China, and is used in roughly 1,000 U.S. classrooms. Founder Sooinn Lee, a former game developer inspired by her son with special needs, aims to boost confidence in young children who struggle with traditional worksheets. The company plans to expand into Asia—initially focusing on China, which accounts for half of its new users—by localizing cultural references and promoting mobile alternatives to paper‑based cram schools. Todo Math is aligned with U.S. Common Core standards and LocoMotive Labs emphasizes adapting content for different curricula during international expansion.